alpha-aminopyridine has been researched along with gsk2256098 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Fiedler, W; Schultze, A | 1 |
| He, DH; Hochwald, SN; Zajac-Kaye, M; Zhang, J | 1 |
| Ali-Fehmi, R; Armaiz-Pena, GN; Coleman, RL; Dalton, HJ; Dorniak, PL; Hansen, JM; Hu, W; Huang, J; Ivan, C; Previs, RA; Rupaimoole, R; Sood, AK; Thanapprapasr, D | 1 |
| Arkenau, HT; Auger, KR; Bahleda, R; Blagden, SP; Brown, J; Dean, E; Evans, TR; Fleming, RA; Gan, HK; Gibson, D; Hollebecque, A; Lemech, C; Mazumdar, J; Millward, M; Murray, S; Nebot, N; Peddareddigari, V; Plummer, R; Ranson, M; Singh, R; Soria, JC; Swartz, L; Zalcman, G | 1 |
| Arkenau, HT; Auger, KR; Blagden, S; Brown, NF; Cox, D; Fleming, RA; Lenox, L; Lewis, Y; Mulholland, P; Plisson, C; Saleem, A; Searle, G; Singh, R; Tolson, J; Williams, M; Yan, L; Zhang, J | 1 |
| Arkenau, HT; Auger, KR; Blagden, SP; Fleming, RA; Gazzah, A; Greystoke, A; Mak, G; Mazumdar, J; Nebot, N; Plummer, R; Rizzuto, I; Rogan, D; Soria, JC; Tolson, J; Yan, L; Zhang, J | 1 |
| Geng, X; He, J; Huang, H; Jenny Lu, HA; Jia, Y; Jin, W; Li, M; Li, X; Meng, J; Qiu, Z; Shao, G; Wang, L; Wang, S; Xu, Y; Yang, B; Zhang, S; Zhou, H | 1 |
1 review(s) available for alpha-aminopyridine and gsk2256098
| Article | Year |
|---|---|
Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Focal Adhesion Kinase 2; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hydroxamic Acids; Indoles; Male; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Pancreatic Neoplasms; Prostatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides | 2011 |
3 trial(s) available for alpha-aminopyridine and gsk2256098
| Article | Year |
|---|---|
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Biopsy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neurofibromin 2; Protein Kinase Inhibitors | 2016 |
A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098.
Topics: Adolescent; Adult; Aged; Aminopyridines; Carbon Radioisotopes; Cohort Studies; Female; Focal Adhesion Protein-Tyrosine Kinases; Follow-Up Studies; Glioblastoma; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Tissue Distribution; Young Adult | 2018 |
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.
Topics: Aged; Aminopyridines; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hydroxamic Acids; Male; Mesothelioma; Middle Aged; Neoplasms; Progression-Free Survival; Pyridones; Pyrimidinones | 2019 |
3 other study(ies) available for alpha-aminopyridine and gsk2256098
| Article | Year |
|---|---|
A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
Topics: Adenocarcinoma; Aminopyridines; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hydroxamic Acids; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt | 2014 |
PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.
Topics: Aminopyridines; Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Female; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hydroxamic Acids; Immunohistochemistry; Ki-67 Antigen; Mice, Nude; Mutation; Neovascularization, Pathologic; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1-Deficient Polycystic Kidney Disease in Animal Model.
Topics: Aminopyridines; Animals; Benzamides; Cell Culture Techniques; Cell Proliferation; Disease Models, Animal; Dogs; Epithelial Cells; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hydroxamic Acids; Mice; Mice, Inbred C57BL; Polycystic Kidney, Autosomal Dominant; Pyrazines; Signal Transduction; Sulfonamides | 2021 |